Join the Endometrial Cancer group to help and get support from people like you.
Endometrial Cancer News
Related terms: Cancer, Endometrial, Cancer, Uterine, Endometrial Adenocarcinoma, Endometrial Carcinoma, Uterine Adenocarcinoma, Uterine Cancer, Uterine corpus cancer
Uterine Cancer Incidence, Mortality Expected to Increase Through 2050
TUESDAY, July 8, 2025 – Uterine cancer incidence and mortality rates are projected to increase significantly through 2050, according to a study published online July 1 in Cancer Epidemiology, ...
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
MONDAY, June 9, 2025 – For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality...
American College of Obstetricians and Gynecologists, May 16-18
The annual meeting of the American College of Obstetricians and Gynecologists (ACOG) was held from May 16 to 18 in Minneapolis and was attended by more than 4,000 clinicians, academicians, allied h...
Black Cancer Death Rate Declining, But Higher Risk Remains
FRIDAY, Feb. 21, 2025 – Cancer deaths among Black men and women in the U.S. have declined during the past decade in the United States, a new American Cancer Society (ACS) report says. The cancer...
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer
THURSDAY, Feb. 20, 2025 – Short-course vaginal cuff brachytherapy (VCB) is noninferior to standard regimens for short-term quality of life in people with early-stage endometrial cancer, according to...
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
MONDAY, Oct. 21, 2024 – Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study...
Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer
WEDNESDAY, Aug. 14, 2024 – For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate, shows...
FDA Expands Jemperli (dostarlimab-gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
Philadelphia, PA – August 01 2024 GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and...
Many Women Don't Know This Warning Sign of Endometrial Cancer
FRIDAY, Aug. 2, 2024 – Too many women don’t know a key warning sign of endometrial cancer, the most common cancer of the female reproductive organs, a new study shows. More than one-third (37%) of w...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Jemperli (dostarlimab-gxly) Plus Chemotherapy Approved in the US for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...
US FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4% 85.9% of patients had duration...
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
KENILWORTH & WOODCLIFF, N.J.--(BUSINESS WIRE) July 22, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
FDA Approves Jemperli (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
London UK 22 April 2021 -- GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking ...
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.-- September 17, 2019 – (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food...